Global veterinary oncology market is estimated to be valued at USD 810.5 Mn in 2025 and is expected to exhibit a (CAGR) of 11.8% during the forecast period (2025-2032). The veterinary oncology market is experiencing significant growth due to rising animal healthcare expenditure and increasing pet ownership. Growing human-animal bonds and rising awareness about cancer in companion animals are propelling demand for advanced diagnostic methods and therapeutic procedures for veterinary oncology. Moreover, increasing incidence of cancers such as lymphoma, mammary tumor, oral melanoma, and mast cell tumors in dogs and cats is driving the need for effective treatment options and early detection. Growing number of veterinary oncologists and oncology specialists along with ongoing research for developing innovative drug formulations are further supporting market expansion on a global level. However, high costs associated with cancer therapies and diagnostic procedures remain a major challenge.

Market Dynamics

The global veterinary oncology market growth is driven by rising incidence of cancer in companion animals, increase in pet insurance purchases, growing animal health expenditure, and technological advancements. According to statistics, over 50% of dogs over the age of 10 will develop cancer and lymphoma is the most common blood cancer in dogs. Rapid urbanization accompanied with rising nuclear families and increasing loneliness levels have boosted pet adoption rates globally. This has led to pet owners becoming more aware regarding the health of their pets and willing to spend more on premium treatments. Various organizations are financially supporting clinical trials and research activities related to veterinary oncology which is playing a significant role in market growth. However, high costs associated with oncology medications, diagnostic tests, surgeries, and lack of awareness in developing nations are anticipated to hamper the market expansion during the forecast period. Ongoing initiatives to spread awareness regarding cancer in pets through social media campaigns and conferences are expected to bring numerous lucrative opportunities for key players in the market.

Key Features of the Study

• This report provides an in-depth analysis of the global veterinary oncology market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global veterinary oncology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Zoetis Inc., Elanco, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, VetDC, Morphogenesis, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., AdvaVet, Inc., Rhizen Pharmaceutical SA., PetCure Oncology, Varian Medical Systems, Accuray Incorporated, One Health, and Regeneus Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global veterinary oncology market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global veterinary oncology market.

Market Segmentation

• By Animal Type
  • Companion Animal
    • Equine
    • Canine
    • Feline
  • Livestock Animal
• By Therapy Type
  • Chemotherapy
  • Combination Therapy
  • Immunotherapy
  • Targeted Therapy
• By Mode of Administration
  • Oral 
  • Intravenous
• By Application
  • Canine Lymphoma
  • Osteosarcoma (OSA)
  • Mast Cell Cancer
  • Melanoma
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Government Agencies
  • Retail Pharmacies
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profiles
  • Zoetis Inc.
  • Elanco
  • AB Science
  • Boehringer Ingelheim International GmbH
  • Zenoaq
  • VetDC
  • Morphogenesis, Inc.
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • AdvaVet, Inc.
  • Rhizen Pharmaceutical SA.
  • PetCure Oncology
  • Varian Medical Systems
  • Accuray Incorporated
  • Merck Animal Health
  • VolitionRx Limited
  • Regeneus Ltd.